Rocket Pharmaceuticals, Inc. Common Stock

RCKTNASDAQ • USD
2.28 USD
↘ 0.01 (0.44%)AT CLOSE (03:59 PM EDT)
2.28
↘ 0.01 (0.22%)
POST MARKET (AS OF 07:31 PM EDT)
Post Market
AS OF 07:31 PM EDT
2.28
↘ 0.01 (0.22%)
🔴Market: CLOSED

Rocket Pharmaceuticals, Inc. Common Stock (RCKT) trades at $2.28 per share. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Oct 26, 2026.

Open?$2.29
High?$2.29
Low?$2.22
Prev. Close?$2.29
Volume?1.5M
Avg. Volume?2.3M
VWAP?$2.26
Rel. Volume?0.67x
Bid / Ask
Bid?$1.93 × 100
Ask?$2.87 × 100
Spread?$0.94
Midpoint?$2.40
Valuation & Ratios
Market Cap?251.4M
Shares Out?109.8M
Float?84.6M
Float %?77.5%
P/E Ratio?N/A
P/B Ratio?0.68
EPS?-$0.16
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Employees
202
Market Cap
251.4M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2015-02-18
Address
350 FIFTH AVENUE
NEW YORK, NY 10118
Phone: 646-440-9100
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
65
Short Sent.?
40
Piotroski F-Score?0/9Weak
Altman Z-Score?-2.50Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?19.25%High
Short Interest?16.3M
Days to Cover?6.7
Free Float84.6M
Avg Daily Volume2.4M
Settlement Date2026-10-15
Financial Health
Current Ratio?9.24Strong
Quick Ratio?9.24Strong
Cash Ratio?7.17Strong
Debt/Equity?0.06Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.68CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.3CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
11
-4.7%WEAK▾
ROA?
S&P
3
-4.1%WEAK▾
Cash Flow & Enterprise
FCF?$-170394000
Enterprise Value?$48.1M
Fundamentals ratios updated end of day